Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 7, 2008, Pages 2383-2388

  Draghi, Deborah C ^a   Benton, Bret M ^b   Krause, Kevin M ^b   Thornsberry, Clyde ^a   Pillar, Chris ^a   Sahm, Daniel F ^a  

^a Eurofins Medinet Inc   (Germany)

^b THERAVANCE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; METICILLIN; PENICILLIN G; TEICOPLANIN; TELAVANCIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; COAGULASE NEGATIVE STAPHYLOCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PROSPECTIVE STUDIES; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 46249125086     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01641-07     Document Type: Article

References (23)

1. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 7th ed. Approved standard M7-A7. Clinical Laboratory Standards Institute, Wayne, PA.
2. Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial susceptibility testing, 17th informational supplement. M100-S17. Clinical Laboratory Standards Institute, Wayne, PA.
3. Diekema, D. J., B. J. Bootsmiller, T. E. Vaughn, R. F. Woolson, J. W. Yankey, E. J. Ernst, S. D. Flach, M. M. Ward, C. L. Franciscus, M. A. Pfaller, and B. N. Doebbeling. 2004. Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin. Infect. Dis. 38:78-85.
4. Draghi, D. C., B. M. Benton, M. E. Jones, K. M. Krause, C. Thornsberry, and D. F. Sahm. 2006. In vitro activity of telavancin against enterococci: results from the 2004-2005 U.S. Surveillance Initiative, abstr. E-0717. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
5. Draghi, D. C., B. M. Benton, M. E. Jones, K. M. Krause, C. Thornsberry, and D. F. Sahm. 2006. Baseline antistaphylococcal profile of telavancin: results of the 2004-2005 U.S. Surveillance Initiative, abstr. E-0715. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
6. Draghi, D. C., D. J. Sheehan, P. Hogan, and D. F. Sahm. 2005. In vitro activity of linezolid against key gram-positive organisms isolated in the United States: results of the LEADER 2004 surveillance program. Antimicrob. Agents Chemother. 49:5024-5032.
7. Goldstein, E. J., D. M. Citron, C. V. Merriam, Y. A. Warren, K. L. Tyrrell, and H. T. Fernandez. 2004. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp. Antimicrob. Agents Chemother. 48:2149-2152.
8. Higgins, D. L., R. Chang, D. V. Debabov, J. Leung, T. Wu, K. M. Krause, E. Sandvik, J. M. Hubbard, K. Kaniga, D. E. Schmidt, Jr., Q. Gao, R. T. Cass, D. E. Karr, B. M. Benton, and P. P. Humphrey. 2005. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49:1127-1134.
9. Jansen, W. T., A. Verel, J. Verhoef, and D. Milatovic. 2007. In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe. Antimicrob. Agents Chemother. 51:3420-3424.
10. Jones, M. E., J. A. Karlowsky, D. C. Draghi, C. Thornsberry, D. F. Sahm, and D. Nathwani. 2003. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int. J. Antimicrob. Agents 22:406-419.
11. Karlowsky, J. A., C. Thornsberry, M. E. Jones, A. T. Evangelista, I. A. Critchley, and D. F. Sahm. 2003. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002). Clin. Infect. Dis. 36:963-970.
12. King, A., I. Phillips, and K. Kaniga. 2004. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration- dependent antiinfective with multiple mechanisms of action against Gram-positive bacteria. J. Antimicrob. Chemother. 53:797-803.
13. Leuthner, K. D., C. M. Cheung, and M. J. Rybak. 2006. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 58:338-343.
14. National Nosocomial Infections Surveillance System. 2003. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 through June 2003, issued August 2003. Am. J. Infect. Control 31:481-498.
15. Pace, J. L., K. Krause, D. Johnston, D. Debabov, T. Wu, L. Farrington, C. Lane, D. L. Higgins, B. Christensen, J. K. Judice, and K. Kaniga. 2003. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob. Agents Chemother. 47:3602-3604.
16. Ross, J. E., T. R. Fritsche, H. S. Sader, and R. N. Jones. 2007. Oxazolidinone susceptibility patterns for 2005: international report from the Zyvox annual appraisal of potency and spectrum study. Int. J. Antimicrob. Agents 29:295-301.
17. Sader, H. S., J. M. Streit, T. R. Fritsche, and R. N. Jones. 2006. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004). Clin. Microbiol. Infect. 12:844-852.
18. Sahm, D. F., M. K. Marsilio, and G. Piazza. 1999. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database-USA. Clin. Infect. Dis. 29:259-263.
19. Stryjewski, M. E., V. H. Chu, W. D. O'Riordan, B. L. Warren, L. M. Dunbar, D. M. Young, M. Vallee, V. G. Fowler, Jr., J. Morganroth, S. L. Barriere, M. M. Kitt, and G. R. Corey for the FAST 2 Investigator Group. 2006. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob. Agents Chemother. 50:862-867.
20. Stryjewski, M. E., D. R. Graham, S. E. Wilson, W. O'Riordan, D. Young, A. Lentnek, D. P. Ross, V. G. Fowler, A. Hopkins, H. D. Friedland, S. L. Barriere, M. M. Kitt, and G. R. Corey on behalf of the Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study. 2008. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin. Infect. Dis. 46:1683-1693.
21. Stryjewski, M. E., W. D. O'Riordan, W. K. Lau, F. D. Pien, L. M. Dunbar, M. Vallee, V. G. Fowler, Jr., V. H. Chu, E. Spencer, S. L. Barriere, M. M. Kitt, C. H. Cabell, and G. R. Corey. 2005. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin. Infect. Dis. 40:1601-1607.
22. Thornsberry, C., D. C. Draghi, B. M. Benton, M. E. Jones, K. M. Krause, and D. F. Sahm. 2006. Baseline profile of telavancin activity against streptococci: results of the. 2004-2005 U.S. Surveillance Initiative, abstr. E-0719. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
23. Watters, A. A., R. N. Jones, J. A. Leeds, G. Denys, H. S. Sader, and T. R. Fritsche. 2006. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004). J. Antimicrob. Chemother. 57:914-923.